Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released April 25, 2017 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)-Along with its success in attracting beach lovers to the mighty Pacific, the U.S. West Coast region is an investment magnet for the Pharmaceutical-Biotech Industry--indeed, for all life-science sectors. The region, which comprises California, Washington, Oregon, Hawaii and Alaska, is on record to launch $1.2 billion in capital and MRO (maintenance) projects during second-quarter 2017.
The life-science industry's capital investment arena is an expensive venture. Depending on the complexity of development or process required by the end user, as well as the location of the project itself, construction costs can reach $1,000 per square foot for full build-out. Factoring in a state like a California, one laden with environmental reviews and seemingly endless permitting hurdles, the planning process can be as intense as the actual construction. While cost and ease of process is always a major consideration, it appears that the strong intellectual capital draw and established industry presence continues to trump the negatives.
According to Industrial Info's Pharmaceutical & Biotech Online Database, the $1.2 billion second-quarter West Coast investment translates into just 28 life-science projects. The average total investment value (TIV) is $43 million, with individual investment values ranging from $1 million to $225 million. As the industry's corporate planners prepare for future capacity needs, along with ensuring a steady stream of new pipeline products, the continued spending is the result of various factors, including long-term projects finally being funded after years of planning. They are a blend of both industry and institutional projects, with a mix of research and manufacturing.
As was the case several years ago when the lines of demarcation became blurred between pharmaceutical and biopharmaceutical companies, as product lines from both found their way under one parent, so now has the relationship between government/institutional entities and corporations. Big Pharma (or Big Bio, as the case may be), increasingly helps to fund and support research efforts on college campuses, along with the growing count of life science business accelerator/incubators.
Click here for access to the 2017 North America Pharmaceutical & Biotech Industry Outlook.
The diversity regarding the type of projects, much like the industry itself, is reflected by a sampling of just three active reports:
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
The life-science industry's capital investment arena is an expensive venture. Depending on the complexity of development or process required by the end user, as well as the location of the project itself, construction costs can reach $1,000 per square foot for full build-out. Factoring in a state like a California, one laden with environmental reviews and seemingly endless permitting hurdles, the planning process can be as intense as the actual construction. While cost and ease of process is always a major consideration, it appears that the strong intellectual capital draw and established industry presence continues to trump the negatives.
According to Industrial Info's Pharmaceutical & Biotech Online Database, the $1.2 billion second-quarter West Coast investment translates into just 28 life-science projects. The average total investment value (TIV) is $43 million, with individual investment values ranging from $1 million to $225 million. As the industry's corporate planners prepare for future capacity needs, along with ensuring a steady stream of new pipeline products, the continued spending is the result of various factors, including long-term projects finally being funded after years of planning. They are a blend of both industry and institutional projects, with a mix of research and manufacturing.
As was the case several years ago when the lines of demarcation became blurred between pharmaceutical and biopharmaceutical companies, as product lines from both found their way under one parent, so now has the relationship between government/institutional entities and corporations. Big Pharma (or Big Bio, as the case may be), increasingly helps to fund and support research efforts on college campuses, along with the growing count of life science business accelerator/incubators.
Click here for access to the 2017 North America Pharmaceutical & Biotech Industry Outlook.
The diversity regarding the type of projects, much like the industry itself, is reflected by a sampling of just three active reports:
- AstaReal Technologies (Moses Lake, Washington) is planning construction of a $30 million, algae-based anti-inflammatory active pharmaceutical ingredients (APIs) contract manufacturing (CMO) plant expansion. Plans call for the existing 59,000-square-foot plant to be expanded by 50,000 square feet.
- Bristol-Myers Squibb is investing $3 million into its site in Redwood City, California. The project will add a 10,000-square-foot protein-engineering lab within its existing 200,000-square-foot facility.
- University of California San Diego is poised to launch construction of its long-awaited Center for Novel Therapeutics (CNT) addition. First reported in 2012, the project will involve the construction of a 110,000-square-foot building (LEED-Silver) and equipment for the research of cancer and related therapeutics. A biotech accelerator (10,000-15,000 square feet) for life sciences startups also will be constructed. The facility will be located on the university's 30-acre Science Research Park on its East Campus in La Jolla.
| PROJECT ID | Project Name |
|---|---|
| 300129476 | BIOTECH CAMPUS REDEVELOPMENT PHASE I |
| 300216621 | RESEARCH INSTITUTE ADDITION |
| 300278722 | R&D BUILDINGS PHASE III |
| 300134321 | MEDICAL SCHOOL RESEARCH PHASE 3.3 |
| 6005363 | SCIENCE II REPLACEMENT BUILDING ADDITION |
| 300067197 | CENTER FOR NOVEL THERAPEUTICS (CNT) ADDITION |
| 300155481 | PHARMACY BUILDING |
| 300343374 | BIOLOGICAL R&D LABORATORY |
| 300236692 | ANTI-INFLAMMATORY (ASTAXANTHIN) API CMO PHASE II |
| 300295794 | MEDICAL CANNABIS (MARIJUANA) PLANT |
| 300304617 | COSMETICS PLANT EXPANSION |
| 300247790 | PROTEINS, VACCINES, GENE/CELL THERAPY SINGLE-USE CMO PLANT ADDITION |
| 300289572 | MAMMALIAN CELL CULTURE BIOMANUFACTURING CMO PLANT ADDITION/RENOVATION |
| 300270224 | THERMOPLASTIC MEDICAL DEVICE CMO PLANT EXPANSION |
| 300349515 | BIOLOGICS & ANTIBODY THERAPEUTICS R&D PROTEIN ENG LAB ADDITION |
| 300313605 | INTRAVENOUS SOLUTION INJECTABLE & CONTAINER PLANT UTILITY SYSTEM UPGRADE |
| 300304469 | TRANSDERMAL NOVEL THERAPEUTICS PLANT EQUIPMENT UPGRADES |
| 300290241 | PARENTERALS CMO & ALLERGENIC EXTRACTS PLANT WAREHOUSE EXPANSION |
| 300271439 | MAMMALIAN CELL-BASED BIOLOGICALS CMO PLANT 2017 MAINTENANCE PROGRAM |
| 300304480 | TRANSDERMAL NOVEL THERAPEUTICS PLANT 2Q17 MAINTENANCE PROGRAM |
| 300342891 | OTC NUTRITIONAL TABLETS, CAPSULES & SOFTGELS CLOSURE DISMANTLE/SALE |
| 300294361 | NEUROLOGICAL MEDICAL DEVICES PLANT CLOSURE, DISMANTLEMENT & RELOCATION |
| 300303983 | CMO GENERIC TABLETS & CAPSULES PLANT EQUIPMENT UPGRADES |
| 300278307 | ASEPTIC PARENTERALS CMO PLANT 2Q17 MAINTENANCE SHUTDOWN |
| 300339803 | RESEARCH ANIMAL PRODUCTION AND LABORATORY EQUIPMENT ADDITION |
| 300296848 | BIOTHERAPEUTICS FILL AND FINISH PLANT (HFF) 2Q17 MAINTENANCE SHUTDOWN |
| 300313914 | DIAGNOSTICS,LIQUIDS,POWDERS & REPRODUCTIVE DEVICES PLANT COLD ROOM ADD |
| 300304196 | OGLIONUCLEOTIDE CMO CRO PLANT CLEANROOM ADDITION |
| 300305786 | DENTAL EQUIPMENT & ORAL HYGIENE PRODUCTS PRODUCTION ROOM ADDITION |
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
